Axxcess Wealth Management LLC Sells 2,744 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Axxcess Wealth Management LLC reduced its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,140 shares of the company’s stock after selling 2,744 shares during the period. Axxcess Wealth Management LLC’s holdings in Recursion Pharmaceuticals were worth $278,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of RXRX. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares during the last quarter. Institute for Wealth Management LLC. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $3,928,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Recursion Pharmaceuticals by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock worth $15,372,000 after buying an additional 333,323 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Recursion Pharmaceuticals by 53.9% in the 3rd quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after buying an additional 244,278 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of research reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $6.68 on Friday. The stock has a market cap of $2.69 billion, a PE ratio of -4.37 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The company has a 50-day moving average price of $7.47 and a 200 day moving average price of $7.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s quarterly revenue was down 57.8% on a year-over-year basis. During the same period last year, the firm earned ($0.42) earnings per share. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.